Based on preclinical models, it has been suggested that CAR-T cells, in addition to targeting cancer cells, may also activate the host immune system [15], and the possible role of an in vivo production of interferon-gamma (IFNγ) has also been hypothesized in a syngeneic mouse glioblastoma model [16]. Here, IFNG is linked to cancer.